NVCR's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 863 -- higher than 96.44% of US-listed equities with positive expected earnings growth.
The price/operating cash flow metric for NovoCure Ltd is higher than 99.03% of stocks in our set with a positive cash flow.
With a price/sales ratio of 17.28, NovoCure Ltd has a higher such ratio than 94.29% of stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to NovoCure Ltd are FIVN, FLGT, FEDU, BMRN, and TRUP.
NovoCure Limited - Ordinary Shares (NVCR) Company Bio
NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.
NVCR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for NovoCure Ltd with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that NovoCure Ltd ranked in the 97th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 15339.17%; returns of such proportions should be viewed with some skepticism, though. As for the metrics that stood out in our discounted cash flow analysis of NovoCure Ltd, consider:
The compound growth rate in the free cash flow of NovoCure Ltd over the past 0.82 years is 4.94%; that's higher than 98.43% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately merely 8.6% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
NovoCure Ltd's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.12. This coverage rate is greater than that of merely 17.61% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
VRTX, DRRX, QHC, ASRT, and THC can be thought of as valuation peers to NVCR, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.